Thursday, May 31, 2012

GSK Looks to Oust HGSI Board; Merck CEO: No Split for Us - May 31, 2012

Having trouble viewing this email? View in Browser.
BioSpace GenePool
   Thursday, May 31, 2012 Advertising Information
subscriptions careernetwork news hotbeds careerfairs
Facebook  |  Linked In  |  Twitter  |  RSS  |  Subscribe

TOP SPONSOR

Pharm-Olam has offices among the most populated cities in Europe, Latin America, India, South Africa, and the USA to provide cost effective coverage for oncology studies of all sizes. Pharm-Olam has helped bring 2 oncology compounds to NDA approval and have conducted oncology studies in over 30 countries. The majority of our clinical staff are MDs or PhDs, including oncologists in strategic areas for clinical trials. The incidence of oncology indications and standards of treatment can vary widely, so let Pharm-Olam conduct a complimentary feasibility study specific to your protocol and study budgets to use in your resource planning.

Contact us at http://www.pharm-olam.com, info@pharm-olam.com, USA 1-713-559-7900, UK 44-0-1344-891121.
Top Stories 
•  GlaxoSmithKline (GSK) Looks to Oust Human Genome Sciences, Inc. (HGSI) Board More...
•  Merck & Co., Inc. (MRK) CEO: No Split for Us More...
•  Chelsea Therapeutics, Inc. (CHTP) Halts Development of Arthritis Drug; Stock Falls -0.63(32.31%) @ 10:33AM EDT More...
•  GlaxoSmithKline (GSK)'s Stiefel Laboratories Pays Welichem Biotech Inc. (WBI.V) $50 Million for Topical Agent for Psoriasis, Atopic Dermatitis More...
•  AssureRx Raises $12.5 Million Series C Financing More...
•  Bayer HealthCare (BAY), Covance Inc. (CVD) Ink Drug Development Pact More...
•  Icahn Takes Another Run at Forest Laboratories, Inc. (FRX) Board More...
•  Vertex Pharmaceuticals Incorporated (VRTX) Goes From Bad Data to a Bad Promotion More...
More Top News
Don't Miss This

JAX® Patient-derived Xenograft Resource

The enormous cost, and high failure rate, of cancer drug development have highlighted the need for new preclinical strategies and resources. To this end, a library of more diverse and representative patient-derived tumor xenograft (PDX) models has been created at The Jackson Laboratory. We utilize NOD scid IL2 receptor gamma chain knockout mice (NSG), constructed by JAX Professor Lenny Shultz, as the mouse host. This PDX resource (which includes tumor gene expression and copy number variation data), developed in collaboration with renowned medical centers throughout the United States, supports large-scale basic and preclinical cancer research and is both affordable and amenable to high throughput studies.

For more information, please visit The Jackson Laboratory.
Featured Stories
•  1 in 4 Medical Sales Job Seekers Forced into Job Search More...
•  Where the Deals are...Cancer Remains Hot More...
•  Oregon Health & Science University (OHSU) Researchers Say Tart Cherries Have "the Highest Anti-Inflammatory Content of Any Food" More...
•  Taste and Smell Control What We Eat, Oregon State University Study More...
•  Fish Fatty Acid Protects Vision in Seniors, University of Alberta Study More...
•  Scientists Map the Tomato's Genome, Cornell University Study More...
•  Potential New HIV Vaccine/Therapy Target, University of California, San Francisco (UCSF) Study More...
•  Humans Can Sniff Out Old Age in Others, Monell Chemical Senses Center Study More...
Tower: Facebook
  More Featured News
Event of the day

SafeBridge Consultants, Inc. announces two Potent Compound Safety Training offerings (may be taken separately or consecutively)

The SafeBridge original Potent Compound Safety "Boot Camp"® (Boot Camp I) is a comprehensive two-day course in pharmaceutical potent compound safety focused on training EH&S and related professionals in critical technical concepts and proactive safety programs in pharmaceutical industrial hygiene, occupational and environmental toxicology, analytical chemistry, and risk communication.

The SafeBridge Advanced Concepts to Support Drug Development of Potent Compounds from R&D through Manufacturing (Boot Camp II) is a one-day advanced course focused on case studies and problem-solving to address potent compound safety issues in discovery, development, contract manufacturing and commercialization.

COURSE SEATING IS LIMITED AND USUALLY SELLS OUT!

Chicago, IL (USA)
Boot Camp I Oct 23-24, 2012
Boot Camp II Oct 25, 2012

Contact: Susan Custer: susan.custer@safebridge.com or 650-961-4820 x 231 or http://www.safebridge.com.
Top Jobs
Biotech Beach (San Diego, California)

Onyx Pharmaceuticals, Inc.
Senior Manager, Corporate Development
Maintain cutting edge scientific knowledge of cancer biology and oncology therapeutics and assess future trends. Attend scientific conferences to scout for opportunities and stay current in field. Represent Onyx in a as a partner of choice to external parties.

Pharm Country (Basking Ridge, New Jersey)

Ipsen
Regulatory Affairs Associate
Reports to the Director of Regulatory Affairs. The position supports the drug development and registration efforts for compounds within the franchise. The candidate will manage and support the regulatory activities necessary to conduct clinical trial and to develop Marketing Application for compound registration.

Genetown (Lexington, Massachusetts)

Shire
Principal Scientist
Will lead a group of scientists and engineers involved in late stage pharmaceutical development of Shire HGT's products. The scope of the work includes formulation development and support of late phase clinical and commercial manufacturing processes.

BioMidwest (Northbrook, Illinois)

Astellas Pharma US
Director, Global Data Management Technical Support
Evaluates and oversees the integration and implementation of new technologies related to the retrieval and processing of data reported on case report forms, transmitted via electronic media, or submitted by CROs contracted to perform data management functions.

Biotech Bay (Pleasanton, California)

Ventana Medical Systems, Inc.
Research Associate III
Responsible for conducting research, development and manufacturing laboratory experimentation and other scientific activities to support Ventana projects. Exercises technical expertise and discretion in the design, execution and interpretation of experiments that contribute to project strategies.

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!
BioSpace Career Fairs

2012 BIO Career Fair

Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Massachusetts region.

Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. (Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.)

Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research.

Job seekers may register here.

2012 BIO Career Fair, Boston, MA June 18, 2012

More information about BioSpace's Career Fairs

BioSpace White Paper
Biotech Career Fairs For Job Seekers 101: Control Your Experience
By June Salvati, BioSpace Director of Events and Corporate Services
Latest Market Insight

Drug Delivery Partnership Strategies

• Learn from interviews with senior drug delivery partnering executives.
• Develop effective partnering strategies based on case studies and analysis of market data.
• Unlock therapeutic value of new biopharmaceutical developments by strategic collaborations for innovative drug delivery technologies.

Click Here for More Information.
Featured Free Resource

Building Novel Applications with Pipeline Pilot to Drive Next Generation Sequencing

This case study shows how scientists are streamlining the process of analyses of DNA sequence information. Enabled by new DNA sequencing technologies, many more scientists and informaticians are interrogating larger and more complex data set.

Request Now!
Company of the day

Technical Resources International, Inc.
Headquarters
6500 Rock Spring Drive, Suite 650
Bethesda, Maryland 20817 U.S.A.
Phone: 301-564-6400 Fax: 301-897-7400

Technical Resources International is a full service technical consulting, management services, and contract research organization. We offer Health, IT, Environmental, and Communications services to government agencies, the private sector, and the non-profit marketplace.

More Company Profiles
Free Resources
FREE Subscription to Biophotonics International

Biophotonics International delivers a unique global insight into the photonic products and techniques that solve problems for researchers, product developers, clinical users, physicians and others actively involved in the field of medicine and biotechnology.
Contact Us

Post Your: News | Jobs | Company Profile | Event | Advertising / Sponsorship

BioSpace Inc.
6465 South Greenwood Plaza, Suite 400
Centennial, Colorado 80111 U.S.A.
Phone: 877-277-7585
Fax: 800-595-2929
BioSpace Inc.
90 New Montgomery Street, Suite 414
San Francisco, California 94105 U.S.A.
Phone: 877-277-7585
Fax: 415-576-9217

Send questions and comments to the BioSpace News Beat Team.

Editor & Publisher: Lana Ho
Editorial & Production Staff: Maysa Darwish, Tammy Liu

BioSpace.com - Life. Science. Community.
Legal Notice

• BioSpace is a registered trademark of BioSpace, Inc.
• Please distribute this e-cast freely.
• Credit any excerpts as follows:
Copyright 2012 BioSpace http://www.biospace.com
• While BioSpace and its agents used their best efforts in collecting and preparing the information published herein, we do not assume, and hereby disclaim, any liability for any loss or damage caused by errors or omissions, whether such errors or omissions resulted from negligence, accident or other causes.
Subscribe/Unsubscribe
If someone forwarded this news to you and you'd like to receive your own copy FREE of charge, simply Subscribe here.

Safely unsubscribe from Biospace.com e-mail at any time by managing your account here.



No comments: